XML 71 R61.htm IDEA: XBRL DOCUMENT v3.24.0.1
Collaboration Agreements, License Agreement and Revenues - Drug Product Revenue - Additional Information (Detail) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2023
Jun. 30, 2023
Dec. 31, 2022
Jun. 30, 2022
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Drug product revenue recognized             $ 147,752 $ 140,734 $ 235,309
Deferred Revenue $ 12,740   $ 12,739       12,740 12,739  
Prepaid Supplies 26,481   17,488       26,481 17,488  
Other long-term liabilities 2,858   6,440       2,858 6,440  
Astra Zeneca Agreements [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Royalty revenue recognized as drug product revenue             89,055    
Drug Product Revenue, Net [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Drug product revenue recognized             18,753 11,086 962
Drug Product Revenue, Net [Member] | API Shipment [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Drug product revenue recognized   $ 1,300             2,100
Drug Product Revenue, Net [Member] | Astellas Agreement [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Drug product revenue recognized             18,800 11,100  
Drug Product Revenue, Net [Member] | Japan [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Drug product revenue recognized   $ 14,400 8,400   $ 9,800        
Drug Product Revenue, Net [Member] | Japan [Member] | API Shipment [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Drug product revenue recognized               8,700  
Drug Product Revenue, Net [Member] | Japan [Member] | Astellas Agreement [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Drug product revenue recognized             15,656 9,480 2,056
Accrued liabilities 1,200   6,500       1,200 6,500  
Other long-term liabilities 700           700    
Drug Product Revenue, Net [Member] | Europe [Member] | Astellas Agreement [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Drug product revenue recognized             3,097 1,606 1,130
Drug Product Revenue, Net [Member] | Europe [Member] | Astellas Europe Agreement [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Burdened manufacturing costs 800     $ 1,000   $ 1,000      
Bulk Drug Product [Member] | Astellas Europe Agreement [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Deferred Revenue 17,700           17,700   8,300
Bulk Drug Product [Member] | Astra Zeneca Agreements [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Drug product revenue recognized               11,200 11,200
Accrued liabilities                 2,200
Bulk Drug Product [Member] | Europe [Member] | Astellas Europe Agreement [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Drug product revenue recognized             38,700 57,400  
Deferred Revenue     23,200         23,200 11,800
Prepaid Supplies                 $ 49,800
Billed Contracts Receivable     $ 49,200         49,200  
Accrued liabilities $ 38,600           38,600    
Bulk Drug Product [Member] | Europe [Member] | Astellas Europe Agreement [Member] | Royalty Revenue [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Royalty revenue recognized as drug product revenue             $ 2,300 $ 600